Scarica l'app Stockscreener
3.451
4.26%
0.141
Precedente Chiudi:
$3.31
Aprire:
$3.34
Volume 24 ore:
16,783
Relative Volume:
0.13
Capitalizzazione di mercato:
$4.97M
Reddito:
$3.50M
Utile/perdita netta:
$-37.33M
Rapporto P/E:
-3.451
EPS:
-1
Flusso di cassa netto:
$-19.15M
1 W Prestazione:
-15.62%
1M Prestazione:
-20.12%
6M Prestazione:
-77.88%
1 anno Prestazione:
-79.51%
Intervallo 1D:
$3.321
$3.48
Intervallo di 1 settimana:
$2.77
$4.32
Portata 52W:
$2.77
$100.80
Hcw Biologics Inc Stock (HCWB) Company Profile
Nome
Hcw Biologics Inc
Settore
Industria
Telefono
954-842-2024
Indirizzo
2929 N COMMERCE PKWY, MIRAMAR
Confronta HCWB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
3.451 | 10.20M | 3.50M | -37.33M | -19.15M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Hcw Biologics Inc Borsa (HCWB) Ultime notizie
HCW Biologics Faces Nasdaq Non-Compliance Notice - MSN
HCW Biologics: Navigating Turbulence in the CAR-T Space—A High-Risk, High-Reward Biotech Play - AInvest
HCW Biologics receives Nasdaq delisting notice, plans to request hearing - Investing.com
Using economic indicators to assess HCW Biologics Inc. potentialPortfolio Value Summary & Safe Capital Growth Stock Tips - Newser
Can HCW Biologics Overcome Liquidity and Legal Risks to Deliver Value? - AInvest
What to do if you’re stuck in HCW Biologics Inc.Portfolio Growth Summary & Long-Term Growth Portfolio Plans - Newser
HCW Biologics Inc. stock outlook for YEAR2025 Historical Comparison & AI Powered Buy and Sell Recommendations - Newser
Detecting support and resistance levels for HCW Biologics Inc.Market Rally & Long-Term Growth Stock Strategies - Newser
Can HCW Biologics Inc. rally from current levelsQuarterly Trade Report & Weekly Setup with High ROI Potential - Newser
HCW Biologics 2025 Q2 Earnings Net Loss Narrows 87.4% - AInvest
HCW Biologics Inc. Sees Relief Buying After Extended DropPrice Action & Daily Entry Point Alerts - 선데이타임즈
Hcw Biologics says substantial doubt exists regarding ability to continue as going concern for at least 12 months - MarketScreener
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results - GlobeNewswire
Clinical-Stage Biotech HCW Biologics Secures $5M Funding for Novel Autoimmune Disease Treatment Trial - Stock Titan
Applying Wyckoff theory to HCW Biologics Inc. stockMarket Growth Review & Fast Exit and Entry Trade Guides - Newser
Real time breakdown of HCW Biologics Inc. stock performanceEntry Point & Safe Entry Zone Tips - Newser
Does HCW Biologics Inc. stock benefit from AI growthWeekly Gains Report & Entry and Exit Point Strategies - mustnews.co.kr
HCW Biologics Inc.’s volatility index tracking explainedJuly 2025 Technicals & Verified Momentum Stock Watchlist - Newser
Why HCW Biologics Inc. stock attracts strong analyst attentionMarket Trend Summary & Risk Controlled Daily Trade Plans - Newser
What drives HCW Biologics Inc.’s stock priceM&A Rumor & Low Volatility Stock Recommendations - classian.co.kr
HCW Biologics Amends Equity Purchase Agreement - MSN
Best data tools to analyze HCW Biologics Inc. stockPortfolio Risk Report & Free Expert Verified Stock Movement Alerts - Newser
Fibonacci Retracement Aligns with Support in HCW Biologics Inc.2025 Sector Review & Short-Term High Return Ideas - sundaytimes.kr
Is HCW Biologics Inc. stock poised for growthWeekly Stock Recap & Target Return Focused Picks - Newser
Will HCW Biologics Inc. stock benefit from interest rate changesTrade Risk Report & Low Risk High Reward Ideas - Newser
HCW Biologics Second Quarter 2025 Earnings: US$0.90 loss per share (vs US$16.16 loss in 2Q 2024) - Yahoo Finance
Will HCW Biologics Inc. rebound enough to break evenMarket Sentiment Review & Free Safe Entry Trade Signal Reports - Newser
HCW Biologics Delays Q2 10-Q Filing - MSN
Exit strategy if you’re trapped in HCW Biologics Inc.Analyst Downgrade & Risk Controlled Daily Plans - Newser
Will HCW Biologics Inc. price bounce be sustainable2025 Retail Activity & Daily Profit Focused Stock Screening - Newser
Is HCW Biologics Inc. reversing from oversold territoryJuly 2025 PreEarnings & Long-Term Investment Growth Plans - Newser
Hcw Biologics Reports Q2 2025 Earnings: Revenue Down 98%, Net Loss Improves to $1.9 Million - AInvest
Hcw Biologics Revenue Plunges 98 Percent - The Globe and Mail
Hcw Biologics Revenue Plunges 98 Percent - The Motley Fool
Published on: 2025-08-14 21:23:14 - newsyoung.net
Long term hold vs stop loss in HCW Biologics Inc.Gap Up & Stepwise Entry and Exit Trade Signals - Newser
What moving averages say about HCW Biologics Inc.Gap Up & AI Forecast Swing Trade Picks - Newser
What recovery options are there for HCW Biologics Inc.Risk Management & Free Expert Verified Stock Movement Alerts - Newser
Market reaction to HCW Biologics Inc.’s recent newsAnalyst Downgrade & Weekly Setup with ROI Potential - Newser
HCW Biologics Inc. stock chart pattern explainedQuarterly Profit Review & Low Risk High Win Rate Stock Picks - Newser
Hcw Biologics Inc Azioni (HCWB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Hcw Biologics Inc Azioni (HCWB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Winer Gary M | Director |
May 16 '25 |
Buy |
7.45 |
1,342 |
9,998 |
4,075 |
| GARRETT SCOTT T | Director |
May 16 '25 |
Buy |
7.45 |
13,423 |
100,001 |
25,505 |
| Winer Gary M | Director |
May 08 '25 |
Buy |
26.00 |
2,308 |
60,008 |
2,733 |
| Wong Hing C | Chief Executive Officer |
May 08 '25 |
Buy |
26.00 |
92,500 |
2,405,000 |
493,857 |
| GARRETT SCOTT T | Director |
May 08 '25 |
Buy |
26.00 |
5,385 |
140,010 |
12,082 |
| Byam Rebecca | Chief Financial Officer |
May 08 '25 |
Buy |
26.00 |
8,462 |
220,012 |
43,010 |
| Flowers Lee | SVP of Business Development |
May 08 '25 |
Buy |
26.00 |
962 |
25,012 |
5,720 |
| Greene Rick S. | Director |
May 08 '25 |
Buy |
26.00 |
962 |
25,012 |
2,066 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):